Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Is glucagon-like peptide-1 fully protected by dipeptidyl peptidase 4 inhibitor administration in patients with type 2 diabetes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Cardiovascular biomarkers in clinical studies of type 2 diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glucose-dependent Insulinotropic Polypeptide (GIP) reduces bone resorption in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Pregnancy loss is associated with type 2 diabetes: a nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Sevelamer is a calcium-free and metal-free phosphate-binding oral drug used in the management of hyperphosphataemia in chronic kidney disease. Preclinical and clinical trials have shown glucose and lipid-lowering effects of sevelamer, thereby giving rise to a potential role of the drug in the treatment of patients with type 2 diabetes. These 'novel' effects are most probably derived from the bile acid-binding properties of sevelamer. The proposed potential is supported by the approval of the bile acid sequestrant colesevelam in the United States for the treatment of type 2 diabetes and hypercholesterolaemia. This article offers a brief review on the effects of sevelamer and a perspective on the potential mechanisms behind the glucose-lowering effect of the drug.

Original languageEnglish
JournalDiabetes, Obesity and Metabolism
Volume17
Issue number2
Pages (from-to)116-120
ISSN1462-8902
DOIs
Publication statusPublished - 9 Jul 2014

Bibliographical note

Diabetes, Obesity and Metabolism
Volume 17, Issue 2, pages 116–120, February 2015

ID: 44858789